Growth factors

Hi-Tech Pharmaceuticals Announced Nationwide Launch of PRO IGF-1® the First Actual IGF-1 in a Dietary Supplement

Retrieved on: 
Wednesday, November 28, 2018
Peptide hormones, Growth factors, Endocrine system, Health, Cell signaling, Endocrinology, Insulin-like growth factor, Nutrition, Pharmaceutical industry in China, Nutraceutical

NORCROSS, Ga., Nov. 28, 2018 /PRNewswire/ --Hi-Tech Pharmaceuticals, Inc., today announced the nationwide launch of its PRO IGF-1 dietary supplement.

Key Points: 
  • NORCROSS, Ga., Nov. 28, 2018 /PRNewswire/ --Hi-Tech Pharmaceuticals, Inc., today announced the nationwide launch of its PRO IGF-1 dietary supplement.
  • Hi-Tech has been able to launch a natural dietary supplement using the extraction of IGF-1 production of Insulin-like growth factor type 1 (IGF-1) from whey protein.
  • Hi-Tech Pharmaceuticals ( https://www.hitechpharma.com/index.htm ) is a leading Sports Nutrition manufacturer.Since 1979, Hi-Tech Pharmaceuticals, Inc. and its sister company, Hi-Tech Nutraceuticals, LLC.
  • Hi-Tech Pharmaceuticals is an enormously successful company that creates, manufactures and sells high-quality products sold by the large, major retailers acrossthe United States.

Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis

Retrieved on: 
Tuesday, November 6, 2018
Biology, Cytokines, Cell biology, Immunology, Growth factors, Immune system, Granulocyte-macrophage colony-stimulating factor, Sargramostim, Pulmonary alveolar proteinosis, Colony-stimulating factor, Macrophage, Monocyte

LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP).

Key Points: 
  • LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP).
  • Leukine works by stimulating the production of white blood cells including neutrophils, monocytes/macrophages and myeloid-derived dendritic cell and promoting their ability to function.
  • The discovery of GM-CSF's role in aPAP led independent researchers to explore Leukine, a recombinant form of GM-CSF, as a potential treatment.
  • The FDA grants orphan drug designation to promote the development of promising treatments for conditions that affect 200,000 or fewer U.S. patients annually.

Shining a Light on Depression - How Infrared Light Can Treat Depression

Retrieved on: 
Monday, October 8, 2018
Neurotrophic factors, Biology, Neuroscience, Biochemistry, Developmental neuroscience, Growth factors, Peptide hormones, Animal anatomy, Brain

Using a unique, high-powered, multi-Watt near-infrared light (NILT), they have shown significant treatment benefit in many patients.

Key Points: 
  • Using a unique, high-powered, multi-Watt near-infrared light (NILT), they have shown significant treatment benefit in many patients.
  • The non-invasive infrared light can safely penetrate the scalp and skull, reaching the brain to re-energize damaged brain cells and activate the brain's own healing processes.
  • "Infrared light delivered properly, can activate brain-derived neurotrophic factor or BDNF," Dr. Henderson explained to the doctors and audience of The Doctors Show .
  • NILT induces regeneration processes and reduces inflammation in the brain and this has proven an effective treatment of depression.

China Epoetin Alfa (EPO) Market, 2018-2022: Concepts, Sales, Manufacturers, Prices & Prospects

Retrieved on: 
Tuesday, July 24, 2018
Growth factors, Medicine, Erythropoiesis-stimulating agents, Clinical medicine, Epoetin alfa, Erythropoietin, Shenyang, China

In June 1989, FDA-approved Epoetin Alfa was launched in the U.S. in the trade name of Epogen.

Key Points: 
  • In June 1989, FDA-approved Epoetin Alfa was launched in the U.S. in the trade name of Epogen.
  • According to the research, in 2017, the sales value of Epoetin Alfa was about CNY 546 million in China.
  • CRI's market research shows that, in recent years, Shenyang Sunshine Pharmaceutical Co., Ltd.'s EPIAO takes up more than half of the Chinese Epoetin Alfa market.
  • The market size of Epoetin Alfa will continue to grow in China from 2018 to 2022 with the economic development and the increase in residents' income.

Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

Retrieved on: 
Monday, July 2, 2018
Biology, Cell biology, Cell signaling, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Brain-derived neurotrophic factor, NMDA receptor, Synaptogenesis, Insulin-like growth factor 1, MTOR

This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.

Key Points: 
  • This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.
  • The data indicate that PKC's synaptogenesis efficacy cannot occur when the NMDA receptor is blocked.
  • We are excited to be presenting this new data at this prestigious international forum" stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.
  • Clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company's views of the Phase 2 data.

FDA approves first epoetin alfa biosimilar for the treatment of anemia

Retrieved on: 
Tuesday, May 15, 2018
Medicine, Growth factors, Clinical medicine, Biology, RTT, Erythropoiesis-stimulating agents, Epoetin alfa, Biotechnology, Erythropoietin, Pfizer, Hospira, Zidovudine

SILVER SPRING, Md., May 15, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Key Points: 
  • SILVER SPRING, Md., May 15, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
  • "Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs."
  • Like Epogen/Procrit, Retacrit must be dispensed with a patient Medication Guide that provides information about the drug's uses and risks.
  • The FDA granted approval of Retacrit to Hospira Inc., a Pfizer company.

US FDA Approves Histogen IND for Female Hair Loss Trial

Retrieved on: 
Thursday, May 3, 2018
Human hair, Biology, Cell biology, Anatomy, Growth factors, Proteins, Vascular endothelial growth factor, Hair follicle, Human hair growth, Hair loss, Follistatin

Hair Stimulating Complex (HSC660) is a soluble formulation of a subset of naturally-secreted growth factors developed as an injectable treatment for hair growth.

Key Points: 
  • Hair Stimulating Complex (HSC660) is a soluble formulation of a subset of naturally-secreted growth factors developed as an injectable treatment for hair growth.
  • Key growth factors within HSC660 include KGF, VEGF, and follistatin, which have been shown to be important in hair formation and the stimulation of resting hair follicles.
  • In addition to seeing a 100% female responder rate in the physician-sponsored study, previous trials have shown efficacy in other difficult-to-treat populations including men over 40 years of age and temporal recession hair loss.
  • Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension.